

ARTICLE OPEN



Biallelic *SH2B3* germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvement

Davide Leardini¹✉, Elisabetta Flex², Elliot Stieglitz³, Sara Cerasi¹, Salvatore Nicola Bertuccio⁴, Francesco Baccelli¹, Krisztián Kállay⁵, Paula Kjollerstrom⁶, Sara Batalha⁶, Giovanna Carpentieri⁷, Lucia Pedace⁸, Andrea Cioffi⁷, Mahmoud Hammad⁹, Maria Miranda¹⁰, Marta Rojas¹¹, Anupama Rao¹², Andrew J. Innes¹³, Martina Rudelius¹⁴, Valeria Santini¹⁵, Marco Raddi¹⁵, Kok-Hoi Teh¹⁶, Rita De Vito¹⁷, Ayami Yoshimi¹⁸, Marco Tartaglia⁷, Franco Locatelli^{8,19}, Charlotte M. Niemeyer¹⁸ and Riccardo Masetti¹

© The Author(s) 2025

Known genetic disorders, such as Noonan syndrome and Down syndrome, can present in the neonatal period or early infancy with myeloproliferative disease (MPD) or abnormal myelopoiesis, which often self-resolves. This phenomenon results from an imbalance in differentiation and cell regulation caused by the genetic condition during perinatal hematopoiesis. Recently, *SH2B3* variants have also been associated with neonatal MPD. However, data on their clinical significance, particularly across the spectrum of extra-hematological manifestations, of *SH2B3* variants remain limited. Here, we describe the clinical features of ten children with *SH2B3*-associated disease, arising from germline biallelic *SH2B3* loss-of-function (LoF) mutations in eight patients and in two patients from monoallelic germline LoF variants with loss-of-heterozygosity in hematopoietic cells. Patients displayed a MPD in the first weeks of life, which was mostly self-limiting. Following the normalization of blood counts, thrombocytosis developed during childhood. Moreover, they presented with a multisystemic clinical features consisting in delayed growth, variable neurological impairment, autoimmune disorders. These data contribute to the definition of a clinical phenotype associated with germline biallelic *SH2B3* LoF variants presenting with neonatal MPD, with important implications for patient management and follow-up.

European Journal of Human Genetics (2025) 33:1127–1135; <https://doi.org/10.1038/s41431-025-01877-y>

INTRODUCTION

Neonatal myeloproliferative disorders (MPDs) are rare conditions associated with genetic disorders such as Noonan syndrome, primarily caused by PTPN11 variants [1], Noonan-like syndromes [2] or Down syndrome [3]. These disorders typically arise during the neonatal period or early infancy and are related to impaired cellular regulatory mechanisms driven by the underlying genetic conditions. Unlike other MPDs, neonatal MPDs are not typically associated with the acquisition of additional somatic mutations, except for the sole acquisition of GATA1 variants in trisomy 21 [3]. In most cases, these conditions resolve spontaneously and occur in the context of broader developmental alterations. Nonetheless, many neonatal MPD remains without a known cause. Recently, *SH2B3* variants, have been associated with peculiar hematological features of the early infancy. The *SH2B3* gene [OMIM 605093] encodes a member of the SH2B adaptor family of proteins, SH2B3,

also known as lymphocyte adaptor protein, LNK, which functions as a negative regulator of multiple cytokine and growth factor receptor signaling pathways, including the JAK/STAT pathway [4, 5]. *SH2B3* is highly expressed in hematopoietic stem and progenitor cells, where it is involved in stem cell expansion and self-renewal, and negatively modulates erythropoiesis and megakaryopoiesis [6–8]. In hematological conditions somatic *SH2B3* variants have been described in 5–7% of patients with myeloproliferative neoplasms (MPN) and, at lower frequency, in juvenile myelomonocytic leukemia (JMML) [9, 10], high-risk B- and early T-cell precursor acute lymphoblastic leukemia (ALL) [4]. Recently, loss-of-function (LoF) germline *SH2B3* variants were reported by two independent groups in patients referred to their reference diagnostic laboratories for JMML who lacked a RAS pathway mutation [9, 10]. They identified eleven children with biallelic germline variants, presenting with peculiar MPD followed by

¹Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ²Istituto Superiore di Sanità, Department Oncology and Molecular Medicine, Rome, Italy. ³Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, CA, USA. ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ⁵Department of Pediatric Haematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary. ⁶Pediatric Hematology Unit, Hospital de Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal. ⁷Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy. ⁸Department of Onco-Hematology, Cell Therapy, Gene Therapy and Hemopoietic Transplant, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy. ⁹National Cancer Institute, Cairo University, Cairo, Egypt. ¹⁰Unidad Nacional de Oncología Pediátrica, Villa Nueva, Guatemala. ¹¹Department of Pediatric Hematology-Oncology, Stollery Children's Hospital, Alberta, AB, Canada. ¹²Department of Hematology, Great Ormond Street Hospital NHS Foundation Trust, London, UK. ¹³Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. ¹⁴Institute of Pathology, Ludwigs Maximilians University, Munich, Germany. ¹⁵MDS Unit, AOUC, University of Florence, Florence, Italy. ¹⁶Department of Pediatrics, Hospital Tunku Azizah, Kuala Lumpur, Malaysia. ¹⁷Pathology Unit, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. ¹⁸Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ¹⁹Catholic University of the Sacred Heart, Rome, Italy.

✉email: davide.lear dini5@unibo.it

Received: 9 January 2025 Revised: 24 March 2025 Accepted: 13 May 2025

Published online: 6 June 2025

thrombocytosis and extra-hematopoietic symptoms. This evidence shadowed some preliminary reports of four patients from three families with biallelic germline *SH2B3* variants. Perez-Garcia et al. reported on a homozygous inactivating *SH2B3* variant in two siblings from a consanguineous marriage with hepatosplenomegaly, leukocytosis that normalized without interventions, anemia in the first weeks of life and subsequently developed B-precursor ALL. Both siblings had impaired growth and mild developmental delay [11]. Blombery et al. reported two non-related infants with a similar leukoerythroblastic picture but thrombocytosis [12]. Of note, the four children later developed autoimmune diseases, including chronic autoimmune hepatitis, Hashimoto thyroiditis, diabetes mellitus and alopecia areata. Germline monoallelic *SH2B3* variants were also found in some patients with familial MPN, myelodysplasia (MDS)/MPN-overlap syndrome with ring sideroblasts, chronic myelomonocytic leukemia, erythrocytosis and immune cytopenia [6, 7, 11–16]. Moreover, *SH2B3* variants have been reported in extra-hematological pathological conditions [17, 18]; specifically, genome-wide studies have associated somatic *SH2B3* polymorphisms with autoimmune diseases, including multiple sclerosis [19], type 1 diabetes [17], and systemic lupus erythematosus [17]. In vitro studies demonstrated that *Sh2b3*-deficient cells exhibited increased JAK2 and STAT3 phosphorylation, indicating enhanced JAK-STAT signaling, and showed increased growth and proliferation, compared with control cells [12]. While increasing evidence is elucidating the role of germline *SH2B3* variants in various disease settings, the broader clinical phenotype remains undefined. Here, we provide a comprehensive description of the hematological and extra-hematological features supported by follow-up data in patients with biallelic germline *SH2B3* variants.

METHODS

This was an international, multicenter, retrospective study on pediatric patients with germline variants in *SH2B3* (NM_005475.3, NP_005466.1). The sole inclusion criterion was the confirmed presence of a germline biallelic or monoallelic with somatic loss of heterozygosity (LOH) *SH2B3* variant, with genetic testing performed at each participating center according to the local protocols. Ten patients from nine centers worldwide were included. Consent for genetic studies and evaluation of clinical data for research had been obtained from patients' guardians according to local procedures. The study design was approved by the Ethical Committee CE-AVEC (code 656/2024/Oss/AOUBo). Clinical information, including disease course and treatment responses, was reported as assessed by the local treating physicians. Bone marrow (BM) examinations, including assessments of BM cellularity, were conducted following local practices. Hematological disorders were classified according to the International Consensus Classification of Myeloid Neoplasms [20]. To examine the structural context of affected residues, UCSF Chimera software (<https://www.cgl.ucsf.edu/chimera/>) [21] was used in combination with the crystallographic structure of the murine *Sh2b3* SH2 domain complexed with the JAK2 pY813 motif (PBD reference: 7r8w).

RESULTS

We report on ten patients with germline *SH2B3* variants; preliminary data from two patients (P4.1, P5.1) were included in a previous report [10]. *SH2B3* variants were identified via clinical NGS assay, on different testing material according to centers' practice as reported in Table 1. The median age at presentation of the six females and four males was 0.2 years (range 0–4.0 years). One patient was lost to follow-up shortly after diagnosis; the median time to follow-up of the remaining patients was 5.0 years (range, 0.7–30.0 years).

Genetic mutational landscape

Eight patients were homozygous or compound heterozygous for germline *SH2B3* variants, two were heterozygous for germline

SH2B3 variants with homozygous variants in hematopoietic cells. All *SH2B3* variants were private/rare (Fig. 1A, Supplementary Table S1), five variants (p.Glu395Lys, p.Lys278Argfs*2, p.Lys278*, p.Gly387*, p.Met1Val) have not been previously reported (Fig. 1A), and three of the families were consanguineous. Among the identified variants, one was a start-loss single nucleotide substitution affecting the initiation codon of the transcript (p.Met1Val), four were frameshift (p.Lys278Argfs*2, p.Lys278*, p.Gly387*, p.Asn570Lysfs*82), and five were missense specifically affecting the SH2 domain of the protein (p.Arg392Trp, p.Arg392Gln, p.Glu395Lys, p.Glu400Lys, p.Leu438Arg), a region largely intolerant to missense variation [22]. Consistently, all variants were classified as likely pathogenic, with the exception of p.Glu400Lys and p.Leu438Arg that were classified as variant of uncertain significance (VUS). Structural inspection of the location of affected residues performed as specified in the Methods [21] showed that Arg392, Glu395, and Glu400 are located close to the phosphorylated Tyr813 residue, and their non-conservative substitutions were predicted to perturb the intermolecular binding network stabilizing *SH2B3* binding to phosphorylated JAK2 (Fig. 1B) [8]. Similarly, the lateral chain of Leu438 points to a buried pocket formed by a number of hydrophobic residues (Trp364, Phe389, Val391, Leu402, Val434, Val435, Met437, and Leu458). The Leu-to-Arg change at codon 438 was predicted to disrupt the structure of this region possibly perturbing proper folding of the SH2 domain. These considerations point to a mechanism for all the identified amino acid changes involving a defective function of the SH2 domain, resulting in impaired binding of *SH2B3* to JAK and its functional downmodulation. Consistent with a LoF model, frameshift variants were spotted throughout the coding sequence of *SH2B3*. A somatic mutation in *SETBP1* (c.1178_1179ins59) at a low variant allele frequency (VAF) of 4% in P 2.1, and a germline VUS in *NF1* (c.7915C>G) at a VAF of 50% in P 9.1 were noted in the cohort.

Hematological presentation

Of the ten patients studied, eight presented with a MPD characterized by leukocytosis with a leukoerythroblastic picture, low blast percentage in BM and splenomegaly, at birth or in the first months of life (Table 1). Median white blood cell count at presentation was $93 \times 10^9/L$ (range 25–170) and median monocyte count $9.2 \times 10^9/L$ (range 3.2–18.1). Immature myeloid and erythroid cells on peripheral blood smear were noted in all patients, while six patients had circulating blast cells. Karyotype was on BM was normal for all patients. The platelet count at the time of MPD diagnosis varied widely among the eight patients, with values ranging from $19 \times 10^9/L$ to $606 \times 10^9/L$. Six patients presented with thrombocytopenia with a median value of $40.5 \times 10^9/L$ (range 19–121), while one had normal platelet levels ($391 \times 10^9/L$), and one had thrombocytosis ($606 \times 10^9/L$). Two patients had a slightly elevated blast percentage in the BM, namely, 7 and 9%. Cytoreductive therapy for MPD was administered to four of the eight patients, which included treatments such as azacitidine, ruxolitinib, venetoclax, 6-mercaptopurine, and two patients underwent splenectomy for rapidly enlarging spleen size. Two patients (P1.1 and P1.2) were treated with allogeneic stem cell transplantation (HSCT) for non-response of myeloproliferation to anti-leukemic agents, one patient (P5.1) for a presumed diagnosis of JMML, and one patient for myelofibrosis at 10 years of age (Table 1). Overall, all patients experienced a complete remission of the MPD. Three of the six patients with MPD and thrombocytopenia (P2.1, P4.1, P6.1) were evaluable for the natural course of their blood counts, which normalized within a few months. However, these patients later developed persistent thrombocytosis at 0.2, 0.8, and 8.0 years of age, with platelet counts ranging from $700 \times 10^9/L$ to $862 \times 10^9/L$ (Table 1, Supplementary Fig. S1). In addition, two of the ten patients in this cohort


Table 1. Mutation, hematological features, and therapy.

ID	Mutation	MPD															
		Germline	Tested specimen	Blood/BM	Age (y)	WBC ($\times 10^9/L$)	% Blasts (PB)	Myeloid/erythroid precursors (PB)	Platelets ($\times 10^9/L$)	% Blasts (BM)	Karyotype (BM)	Splenomegaly/Hepatomegaly	Therapy (months)	Age (y) at first diagnosis noted	Platelets ($\times 10^9/L$) at diagnosis	Splenomegaly	Therapy (years)
P1.1	p.Arg392Trp	Homo	Hair follicle	Homo	0.1	93	6	+	121	7	Normal	+	Aza, splenectomy (6), HSCT (7)	Not evaluable following splenectomy/HSCT			
P1.2	p.Arg392Trp	Homo	Hair follicle	Homo	0	101	2	+	35	2	Normal	+	Aza, ruxo, ven, splenectomy (4), HSCT (9)	Not evaluable following splenectomy/HSCT			
P2.1	p.Asp570Lysfs*82	Homo	Buccal swab	Homo	0	No data	11	+	19	No data	Normal	+	none	8.0	700	+	HSCT ^a (10)
P4.1	p.Leu438Arg	Homo	Hair follicle	Homo	0	25	3	+	33	9	Normal	+	Cytarabine, 6-MP	0.8	862	+	none
P5.1	p.Arg392Gln	Homo	Hair follicle	Homo	0.4	102	5	+	75	4	Normal	+	HSCT (16)	No thrombocytosis prior to HSCT			
P6.1	p.Lys278 ^b	Homo	Hair follicle	Homo	0.1	170	0	+	46	2	Normal	+	6-MP	0.2	770	+	6-MP
P8.1	p.Lys278Argfs*2	Hetero	Hair follicle	Homo	0.2	46	4	+	606	0	Normal	+	none	0.2	606 ^b (1100 at 4 y of age)	+	none
P9.1	p.Gly387 ^a	Hetero	Hair follicle	Homo	0.7	36.9	2	+	391	1	Normal	+	none	Lost to follow-up after initial presentation			
P3.1	p.Met1Val	Homo	Hair follicle	Homo	Not presented	MPD								0.3	1160	-	none
P7.1	p.Glu400Lys p.Glu395Lys	Compound hetero	Skin fibroblasts	Homo	Not presented	MPD								4.0	1077	+	none

Aza azacytidine, BM bone marrow, HSCT hematopoietic stem cell transplantation, 6-MP 6-mercaptopurine, MPD myeloproliferative disease, PB peripheral blood, ruxo ruxolitinib, ven venetoclax, WBC white blood cells, Y year.

^aPatient was transplanted for myelofibrosis grade 3.

^bPlatelet count at initial presentation, see also under MPD.



(P3.1, P7.1), who did not present with MPD, displayed isolated, as the sole hematological feature, persistent thrombocytosis diagnosed at 0.3 and 4.0 years of age, with platelet counts of $1160 \times 10^9/L$ and $1077 \times 10^9/L$, respectively. These two patients were diagnosed during routine blood tests. None of the 6 patients

with patients with thrombocytosis experienced symptoms associated or required specific treatments for this platelet elevation. On peripheral blood smear, there was marked anisocytosis of platelets with giant platelets (Fig. 2A, C). Leukocytosis with atypical monocytosis was present and the percentage of eosinophils was

Fig. 1 Genetic and structural characterization of SH2B3 germline variants in the study cohort. **A** The upper section shows the distribution of SH2B3 variants in the study cohort on the SH2B3 protein. Mutations in bold have not been previously reported. The lower section presents published SH2B3 germline variants. PH: Pleckstrin homology domain; Phe-ZIP: Phenylalanine zipper; SH2: SH2 domain. #Mutation in trans on IGV variant viewer. **B** Location of Arg392, Glu395, Glu400, and Leu438 within the SH2 domain of SH2B3. The panel shows the SH2 domain (pink) complexed with the JAK2 peptide containing pTyr813 (light blue) (PBD: 7r8w). Three residues (Arg392, Glu395, and Glu400) are located close to pTyr813 and their non-conservative substitutions are predicted to perturb the intermolecular binding network stabilizing the SH2B3-JAK2 interaction (left). The mutated residues are highlighted in yellow with their lateral chains. The lateral chain of Leu438 is placed in a buried pocket formed by several hydrophobic residues (Trp364, Phe389, Val391, Leu402, Val434, Val435, Met437, Leu458; lateral chains showed in green). The Leu-to-Arg substitution introduces a positively charged lateral chain that is expected to dramatically perturb the conformational organization of the region, likely resulting in an aberrant folding of the entire SH2 domain (right). Both events are predicted to result in a defective function of the SH2 domain, causing AQ9 impaired binding of SH2B3 to JAK, and failure to functionally downmodulate the kinase. **C** Pedigrees for seven patients. Individual with a homozygous mutation or compound heterozygous or with a homozygous mutation on hematopoietic stem cells in each family are marked with arrows. Double line indicates consanguinity, which is present in three families. MPD myeloproliferative disorder; NA not assessed; wt wild-type; * SH2B3 variant.

often elevated. Myeloid, as well as erythroid, precursors were noted. BM aspirate showed an increased number of megakaryocytes with enlarged and abundant cytoplasm and hyperlobulated nuclei (Fig. 2B, D). Myelopoiesis was hyperplastic and left shifted. Erythropoiesis was hypoplastic without significant dysplasia. BM biopsies were performed during the initial diagnostic assessment in three patients (P1.1, P1.2, P2.1). Morphological analysis revealed a hypercellular marrow with hyperplastic megakaryopoiesis forming large clusters (Fig. 2E–H). The megakaryocytes themselves appeared atypical and polymorphic with a prevalence of enlarged and hyperlobulated cells. Granulopoiesis was increased and left-shifted with a slight increase in eosinophils. Erythropoiesis was significantly reduced with an increase in immature precursors. There was neither evidence of BM fibrosis nor significant proliferation of monocytes or myeloblasts.

Extra-hematological features and family study

Most of the patients presented with extra-hematological features (Table 2). Eight patients presented with intrauterine growth restriction (IUGR) or were small for gestational age, and two patients had been delivered pre-term. Median birth weight was 2000 g (range, 1400–3570). One patient (P8.1) presented with severe cognitive impairment. Six others had developmental delay; among the four children who underwent formal psychological assessment, three (P2.1, P4.1, P5.1) had normal results, while one (P6.1) showed mild cognitive impairment. Five patients showed dysmorphic features, which included low-set, posteriorly rotated ears, a prominent forehead with a high hairline, mild hypertelorism, absence of one finger in the right hand, and microcephaly. For the two patients with microcephaly (P5.1 and P6.1), the condition was not present at birth but was noted during growth monitoring. Two patients developed autoimmune diseases during childhood at a median age of 10 years (range 9–11). Nine relatives of six index cases were studied for SH2B3 variants (Fig. 1C). Two siblings of index cases presented monoallelic SH2B3 variants; one (sister of P2.1) was free of symptoms, while the other (brother of P3.1) had moderate thrombocytosis (value of $500 \times 10^9/L$) since birth. Among the five parents carrying monoallelic germline variants, only one subject (mother of P3.1) had persisting JAK2-negative thrombocytosis since the age of 15 years and Crohn's disease with arthritis and vitiligo (value of $>1.000 \times 10^9/L$ in more than one determination, normal the rest of complete blood count). The other parents were asymptomatic with normal blood counts.

DISCUSSION

We here describe the clinical features of a cohort of 10 patients with germline SH2B3 variants. In our cohort, biallelic SH2B3 variants were associated in eight patients with MPD in the first weeks of life, including two with a monoallelic germline variant who acquired somatic LOH. Considering the age of onset of the

phenotype, respectively at 0.2 and 0.7 years, the two patients most likely acquired LOH for the SH2B3 variant pre- or early postnatally and thus it is conceivable that the observed phenotype is related to the biallelic alteration of the gene. This suggests that the LOH occurred through a uniparental disomy (UPD) mechanism or a gene loss during early hematopoiesis, may lead to clonal expansion of hematopoietic cells. Interestingly, the VAF in blood for patient P8.1 who carries a monoallelic variant in germline material, was close to 100%, suggesting a near-complete replacement of normal hematopoiesis by the mutant clone. Unfortunately, detailed VAF dynamics pre- and post-treatment were not available for this patient. However, tracking changes in VAF over time could provide valuable insights into the clonal dynamics and the extent to which normal hematopoiesis can recover following the resolution of MPD. This observation is particularly novel and has significant implications for understanding the pathogenesis of SH2B3-related disorders. The mechanism of LOH is reminiscent of what is commonly observed in JMML, where somatic or acquired UPD is a well-recognized driver of clonal dominance. Future studies investigating the role of similar LOH mechanisms in SH2B3-related disorders may uncover parallels to other hematopoietic conditions and improve our understanding of disease progression and variability in clinical phenotype.

The clinical course is characterized by leukoerythroblastosis, monocytosis, low blast percentage in blood and marrow, splenomegaly, a normal karyotype and absence of somatic mutations. This presentation of the constitutional SH2B3-related disease is reminiscent of that observed in other MPD in neonates or infants, such as in patients with Down syndrome with somatic mutations in GATA1, or in RASopathies associated with germline mutations in CBL or PTPN11. In particular, MPD in CBL syndrome characterized by monoallelic germline mutation and LOH in hematopoietic cells, runs a self-resolving clinical course in the vast majority of cases. Interestingly, SH2B3 recruits the CBL protein via its conserved C-terminal tyrosine residue leading to an interaction between JAK-STAT and RAS-MAPK signaling. This interaction suggests that SH2B3 loss-of-function promotes myeloproliferation by activating the RAS-MAPK pathway through altered CBL modulation [2, 23, 24]. This was confirmed in transgenic mouse models, where the loss of both Lnk and Cbl leads to severe splenomegaly, extramedullary hematopoiesis, and exacerbated myeloproliferative characteristics [25] and reported in a previous case report [15]. Like in previous reports [9, 11, 12], the clinical course of neonatal MPD in patients with SH2B3 germline disease presented here was self-limiting in most cases. Three patients did not receive any therapy; two patients were treated with low dose cytoreductive therapy to ameliorate myeloproliferation. In two patients, chemotherapy and BCL-2 inhibition failed to control the disease, suggesting that some cases of SH2B3-related neonatal MPD may not run an indolent course. Considering the preclinical evidence of JAK-inhibition in




Fig. 2 Peripheral blood and bone marrow findings in patients with SH2B3 germline variants. Peripheral blood **A, C** and BM aspirate **B, D** of P8.1 **A, B** and P9.1 **C, D**: Anisopoikilocytosis of red blood cells with teardrops, increased platelets with anisocytosis and giant platelets **A** Enlarged megakaryocyte with abundant cytoplasm and hyperlobulated nucleus **B**. Myelocyte and atypical monocytes. **C** Hyperplastic and left shifted myelopoiesis **D**. BM biopsy of patient P1.1 **E–H**: Hypercellular BM **E, H**, **E** with clusters of atypical, enlarged megakaryocytes (**F, H, E**; 4x magnification of **E**). Increased granulopoiesis (**G**; MPO immunohistochemistry) and reduced and left shifted erythropoiesis (**H**; CD71 immunohistochemistry).

SH2B3-mutant cells [10, 12], ruxolitinib could be an attractive therapy option. In the previous report ruxolitinib was effective in the resolution of splenomegaly and in the reduction of SH2B3 variant allele frequency [10]. In our cohort, ruxolitinib did not show efficacy in the treated patient. All patients in our cohort were alive at the last follow-up, including the three who received allogeneic HSCT, and none presented with abnormal blood counts except for thrombocytosis.

Indeed, the clinical presentation of these MPD also resembles JMML. Not surprisingly, SH2B3 variants have been identified in neonates suspected of JMML who lack a RAS pathway mutation, as reported in previous studies [9, 10]. The challenges and inconsistencies in categorizing these unique MPD in young

children are further highlighted by the fact that MPD in CBL syndrome is traditionally classified as JMML. Arfeuille et al. reported on eight such patients from five families carrying biallelic germline variants [9]. Notably, while in our cohort the clinical phenotype shared features with JMML, the morphology, in particular the prominent atypical megakaryopoiesis and the absence of a significant increase in monocytic cell forms, was not characteristic of JMML [26]. However, since we evaluated BM specimens obtained in early infancy and not in the neonatal period, it is conceivable that the number of megakaryocytes in affected newborns is reduced as described by the French investigators [9], and the dysplastic features described arise later in early infancy.

Table 2. Extra-hematological features.

ID	Geographic region	Consanguineous parents	Sex	Birth's week	Weight at birth (g)	IUGR /SGA	Growth retardation /small stature	Dysmorphic features	DD/cognitive impairment	Autoimmune manifestation (y)	Follow-up (age in years)
P1.1	HU	Yes	F	38	1490	+	+	Low-set and posteriorly rotated ears; prominent forehead with high hair line, mild hypertelorism	Speech and walking delay	—	Alive (1.9)
P1.2	HU	Yes	F	40	2280	+	+	Same than P1.1	Same than P1.1	—	Alive (0.7)
P2.1	ITA	Yes	F	36	2000	+	+	—	Speech and walking delay, no cognitive impairment	Multiple sclerosis (9) Diabetes mellitus (10)	Alive (14.4)
P4.1	CAN	Unknown (parents from the same indigenous reserve)	M	33	1490	+	—	Absence of one finger in the right hand	Speech delay	—	Alive (5.0)
P5.1	EGY	Yes	F	40	1800	+	+	Microcephaly	Speech and walking delay	—	Alive (1.7)
P6.1	GBR	Unknown	M	40	2010	+	+	Microcephaly	Mild global developmental delay and cognitive impairment	Autoimmune hypothyroidism (10) Localized scleroderma (11)	Alive (15.0)
P8.1	MYS	Unknown	F	40	1400	+	+	—	Severe cognitive impairment, autism	—	Alive (4.0)
P9.1	GTM	Unknown	F	No data	No data	No data	—	—	—	Lost to follow-up	—
P3.1	PRT	No	M	39	3570	—	—	—	—	—	Alive (12.0)
P7.1	GBR	No	M	42	2700	+	—	—	—	—	Alive (34.0)

CAN Canada, DD developmental delay, EGY Egypt, GBR Great Britain, GTM Guatemala, HU Hungary, ITA Italy, IUGR intrauterine growth restriction, MRI magnetic resonance imaging, MYS Malaysia, PRT Portugal, SGA small for gestational age.

In our cohort, following the resolution of MPD, patients with biallelic germline disease developed persistent thrombocytosis. One of these children underwent allogeneic HSCT for myelofibrosis at 10 years of age. In two other patients in this cohort (P 3.1, P 7.1), thrombocytosis diagnosed at 0.3 years and 4 years of age was the sole initial hematological presentation. Interestingly, the two children with monoallelic germline variants and LOH in hematopoietic cells had normal or moderately elevated platelet counts when neonatal MPD was diagnosed. The observation of thrombocytosis is consistent with the role of SH2B3 as a negative regulator of JAK/STAT signaling as previously demonstrated [4, 10, 12], also demonstrated by the increase in megakaryocytic progenitors, megakaryocytes, and platelets in hematopoietic tissue, along with an increase in erythroid progenitors, reported in *Sh2b3*-deficient mice [27]. Notably, the impact of SH2B3 LoF appears to be age-dependent with features of MPD in newborns and young infants and isolated thrombocytosis later in childhood, suggesting that *SH2B3* variants have different effects on fetal and adult hematopoiesis. Remarkably, the mother of patient 3.1, who carries a heterozygous germline variant, has been known to have thrombocytosis since adolescence. Considering the clinical phenotypes associated with germline *SH2B3* variants, it is puzzling that they can cause thrombocytosis or erythrocytosis in the absence of somatic mutations [28], while also cooperating with other driver mutations such as *JAK2* or *CALR* to result in adult-type MPD [6, 7, 13, 14, 29], or *PTPN11* to result in JMML. It must be said that one patient in our cohort presented a germline *VUS* in *NF1*; however, the patient did not develop any sign or symptoms of *NF1*-related conditions.

Given the lack of robust data on the long-term outcomes of this rare hematological disorder, a watch-and-wait strategy appears to be a reasonable initial approach, as suggested by others [9, 10]. In cases of extreme leukocytosis with pulmonary complications or significant organomegaly, cytoreductive therapy with 6-mercaptopurine or low-dose cytarabine may provide symptomatic relief. Later in the clinical course, disturbed megakaryopoiesis may lead to progressive myelofibrosis, resulting in an indication for HSCT.

Previous reports have described associations between germline *SH2B3* variants and specific autoimmune conditions [9, 10, 17, 30]. In the presented cohort, six patients with biallelic *SH2B3* germline variants and one of the two patients with a monoallelic germline variant and LOH in hematopoietic tissue displayed extra-hematopoietic symptoms, including IUGR, developmental delay, growth retardation, and dysmorphic facial features. Indeed, IUGR appears to be the most consistent constitutional phenotype. The underlying mechanism of this delay remains unclear, but one possibility is that it represents a hypoproliferative phenotype, potentially driven by an embryonic effect of SH2B3. To explore this, we examined available complete blood count data at birth in two patients who later developed MPD (P1.1 and P1.2), both of whom had normal hemoglobin levels. This very preliminary finding suggests that the phenotype may be more consistent with an intrinsic hypoproliferative mechanism rather than anemia-induced growth restriction. The presence of extra-hematological pathological features in both monoallelic and biallelic variant patients, suggest that a single hit may be sufficient to produce a phenotype. Indeed, the high incidence of these abnormalities in families with consanguineous parents may be a confounding factor, and larger cohorts will help define these clinical features [12]. Arfeuille et al. reported extra-hematological features as well, including cardiac involvement, which we did not confirm in ours [9]. Our report also underlines the frequent development of autoimmunity manifesting itself in childhood [9, 11, 12]. The role of SH2B3 in autoimmunity is suggested by earlier genome-wide studies in a variety of autoimmune disorders like rheumatoid arthritis, coeliac disease, hepatitis or diabetes type 1 [19, 31–35].

Moreover, it was shown that *SH2B3* variants in patients with systemic lupus erythematosus are predominantly hypomorphic alleles failing to suppress interferon type II signaling via JAK2-STAT1 and impairing the negative selection of self-reactive B cells in mice [30]. This evidence may explain the high incidence of autoimmunity in these patients. However, further functional *in vivo* studies, including the exploration of biological markers related to cellular and humoral immunity, will be necessary to better characterize potential immune deregulations that contribute to their susceptibility to autoimmune diseases in late childhood. Apart from a distinct hematological phenotype, there are overlapping extra-hematopoietic features such as IUGR, growth retardation, and developmental delay. However, dysmorphic features appear more variable among individuals and larger cohorts will be essential to clarify whether these findings define a consistent syndrome.

To summarize, germline *SH2B3* LoF variants define a novel condition characterized by neonatal or in early infancy MPD which appears to be associated with extra-hematopoietic symptoms. Awareness of this genetic condition is key to a correct diagnosis and avoidance of unnecessary intensive therapy for the MPD. The establishment of large international registries spanning all age groups will be essential to better characterize the natural history of germline *SH2B3* disease and to enhance our understanding of SH2B3 function across different ages and hematological manifestations.

DATA AVAILABILITY

The original data of the current study are available from the corresponding author on reasonable request.

REFERENCES

- Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. Diversity and functional consequences of germline and somatic *PTPN11* mutations in human disease. *Am J Hum Genet.* 2006;78:279–90.
- Leardini D, Messelodi D, Muratore E, Baccelli F, Bertuccio SN, Anselmi L, et al. Role of *CBL* mutations in cancer and non-malignant phenotype. *Cancers.* 2022;14:839.
- Roberts I. Leukemogenesis in infants and young children with trisomy 21. *Hematol Am Soc Hematol Educ Program.* 2022;2022:1–8.
- Maslal N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L. The role of *LNK/SH2B3* genetic alterations in myeloproliferative neoplasms and other hematological disorders. *Leukemia.* 2017;31:1661–70.
- Niemeyer CM, Erlacher M. *SH2B3* alterations in a novel genetic condition, juvenile myelomonocytic leukemia, and myeloproliferative neoplasia. *Haematologica.* 2024;109:2391–4.
- Rumi E, Harutyunyan AS, Pietra D, Feenstra JDM, Cavalloni C, Roncoroni E, et al. *LNK* mutations in familial myeloproliferative neoplasms. *Blood.* 2016;128:144–5.
- Gundabolu K, Dave BJ, Alvares CJ, Cannatella JJ, Bhatt VR, Maness LJ, et al. The Missing *LNK*: Evolution from cytosis to chronic myelomonocytic leukemia in a patient with multiple sclerosis and germline *SH2B3* mutation. *Case Rep Genet.* 2022;2022:6977041.
- Morris R, Butler L, Perkins A, Kershaw NJ, Babon JJ. The Role of *LNK (SH2B3)* in the Regulation of JAK-STAT signalling in haematopoiesis. *Pharmaceuticals.* 2021;15:24.
- Arfeuille C, Vial Y, Cadenet M, Caye-Eude A, Fenneteau O, Neven Q, et al. Germline bi-allelic *SH2B3/LNK* alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder. *Haematologica.* 2024;109:2542–54.
- Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, et al. *LNK/SH2B3* as a novel driver in juvenile myelomonocytic leukemia. *Haematologica.* 2024;109:2533–41.
- Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K, et al. Genetic loss of *SH2B3* in acute lymphoblastic leukemia. *Blood.* 2013;122:2425–32.
- Blombery P, Pazhakh V, Albuquerque AS, Maimaris J, Tu L, Briones Miranda B, et al. Biallelic deleterious germline *SH2B3* variants cause a novel syndrome of myeloproliferation and multi-organ autoimmunity. *EJHaem.* 2023;4:463–9.
- Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, et al. Germline *SH2B3* pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *Am J Hematol.* 2019;94:E231–4.
- Loscocco GG, Mannarelli C, Pacilli A, Fanelli T, Rotunno G, Gesullo F, et al. Germline transmission of *LNKE208Q* variant in a family with myeloproliferative neoplasms. *Am J Hematol.* 2016;91:E356.

15. Baccelli F, Leardini D, Muratore E, Messelodi D, Bertuccio SN, Chiriaco M, et al. Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants. *Hum Genom.* 2022;16:40.
16. Vermeersch G, Devos T, Devos H, Lambert F, Poppe B, Van Hecke S. Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation. *EJHaem.* 2023;4:1143–7.
17. Vandewalle J, Desouter AK, Van der Auwera BJ, Tenoutasse S, Gillard P, De Block C, et al. CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients. *Clin Exp Immunol.* 2023;211:224–32.
18. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, et al. A genome-wide association study of a coronary artery disease risk variant. *J Hum Genet.* 2013;58:120–6.
19. Alcina A, Vandebroek K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O, et al. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. *Genes Immun.* 2010;11:439–45.
20. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood.* 2022;140:1200–28.
21. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. *J Comput Chem.* 2004;25:1605–12.
22. Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome: Pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. *Human Mutat.* 2019;40:1030–8.
23. Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, et al. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. *Genes Dev.* 2017;31:1007–23.
24. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. *Cancer Cell.* 2008;14:335–43.
25. Chen Y, Gong S, Tang J, Wang X, Gao Y, Yang H, et al. LNK/SH2B3 Loss Exacerbates the Development of Myeloproliferative Neoplasms in CBL-deficient Mice. *Stem Cell Rev and Rep.* 2024; Disponibile su: <https://link.springer.com/10.1007/s12015-024-10825-0>.
26. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. *Br J Haematol.* 2008;140:610–24.
27. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. *J Exp Med.* 2002;195:1599–611.
28. McMullin MF. Congenital erythrocytosis. *Int J Lab Hematol.* 2016;38:59–65.
29. Beghini A, Leuzzi L, Abazari N, Bossi LE, Guido V, Trojani A, et al. A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms. *Hematol Oncol.* 2022;40:1109–12.
30. Zhang Y, Morris R, Brown GJ, Lorenzo AMD, Meng X, Kershaw NJ, et al. Rare SH2B3 coding variants in lupus patients impair B cell tolerance and predispose to autoimmunity. *J Exp Med.* 2024;221:e20221080.
31. Hunt KA, Zhernakova A, Turner G, Heap GAR, Franke L, Bruinenberg M, et al. Newly identified genetic risk variants for celiac disease related to the immune response. *Nat Genet.* 2008;40:395–402.
32. Coenen MJH, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, et al. Common and different genetic background for rheumatoid arthritis and coeliac disease. *Hum Mol Genet.* 2009;18:4195–203.
33. Zhernakova A, Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC, et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. *Am J Hum Genet.* 2010;86:970–7.
34. Engel B, Laschtowitz A, Janik MK, Junge N, Baumann U, Milkiewicz P, et al. Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. *Eur J Med Genet.* 2021;64:104214.
35. Michalek DA, Tern C, Zhou W, Robertson CC, Farber E, Campolieto P, et al. A multi-ancestry genome-wide association study in type 1 diabetes. *Hum Mol Genet.* 2024;33:958–68.

ACKNOWLEDGEMENTS

The authors acknowledge the contribution of the Center of Inborn and Acquired Blood Diseases at the Freiburg Center for Rare Diseases, and the Hilda Biobank at the Department of Pediatrics and Adolescent Medicine, Freiburg, Germany. This work was supported, in part, by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG-26537-2021 to V.S.; IG-21614 and IG-28768 to M.T.; IG-26039 to R.M.); EJP-RD (NSEuroNet to M.T.); Italian Ministry of Health (Current Research Funds and 5x1000 to M.T.); by the German Federal Ministry of Education and Research (BMBF) 01GM1911A “MyPred - Network for young individuals with syndromes predisposing to myeloid malignancies” to C.M.N. and A.Y.. This work was generated within the European Reference Network for Paediatric Cancer (PAEDCAN).

AUTHOR CONTRIBUTIONS

DL and RM conceptualized the research; DL, CMN, and RM wrote the manuscript; DL and CMN prepared the figures; DL, SC, FB collected the clinical data; SNB analyzed the genetic data; ES, KK, PK, SB, LP, FL, VS, MRa, MH, MM, MRo, AR, AJI, and KT diagnosed and treated the patients; EF, GC, and AC, and MT performed the structural and functional annotation analyses; MR, RDV, and AY performed the cytological and histopathological analysis; MT, FL, CMN, and RM supervised the research and critically reviewed the paper.

FUNDING

The work was in part supported by the Italian Ministry of Health, RC-2025-2797529.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

Written parental and patient consent had been obtained by the contributing centers following a review by the respective local Ethic Committee.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41431-025-01877-y>.

Correspondence and requests for materials should be addressed to Davide Leardini.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025